Vertex Pharmaceuticals Inc (LTS:0QZU)
$ 469.77 -0.73 (-0.16%) Market Cap: 120.84 Bil Enterprise Value: 116.02 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 91/100

Vertex Pharmaceuticals Inc to Host Conference Call Transcript

Dec 13, 2023 / 01:00PM GMT
Release Date Price: $399.71 (+11.82%)
Operator

Good day, and welcome to the Vertex Pharmaceuticals review of VX-548 Phase 2 Results in Diabetic Peripheral Neuropathy Conference Call. (Operator Instructions) I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead.

Susie Lisa
Vertex Pharmaceuticals Incorporated - SVP of IR

Thanks, Chuck. Good morning, everyone. I'm Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to this conference call to discuss results from Vertex's Phase 2 study of VX-548 in diabetic peripheral neuropathy, or DPN. Making prepared remarks on today's call, we have Dr. Reshma Kewalramani, Vertex's CEO and President.

Joining her for the question-and-answer portion of the call are Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast live as you listen to this call. The call is being recorded, and a replay will be available on our website.

We will make forward-looking statements on this call that are subject to the risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot